Lakefront Biotherapeutics (GLPGF) Revenue Growth (5y) (2019 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Revenue Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.11% |
| Mar 31, 2026 | -43.97% |
| Dec 31, 2025 | 10.65% |
| Sep 30, 2025 | -26.05% |
| Jun 30, 2025 | -7.58% |
| Mar 31, 2025 | -7.16% |
| Dec 31, 2024 | -47.24% |
| Sep 30, 2024 | -26.56% |
| Jun 30, 2024 | -19.23% |
| Mar 31, 2024 | 12.54% |
| Dec 31, 2023 | 39.74% |
| Sep 30, 2023 | -9.60% |
| Jun 30, 2023 | 1.97% |
| Mar 31, 2023 | 6.19% |
| Dec 31, 2022 | -41.80% |
| Sep 30, 2022 | 34.10% |
| Jun 30, 2022 | 37.75% |
| Mar 31, 2022 | 33.41% |
| Dec 31, 2021 | -40.32% |
| Jun 30, 2021 | 39.04% |